Biogen and Sage Therapeutics to jointly develop therapies in depression and movement disorders

This article was originally published here

As per terms of the deal, Sage will secure $1.525 in cash that includes an upfront payment of $875m and $650m equity investment, as well as potential milestone

The post Biogen and Sage Therapeutics to jointly develop therapies in depression and movement disorders appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply